By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Kolltan Pharmaceuticals Inc. 

300 George Street
Suite 530
New Haven  Connecticut  06511  U.S.A.
Phone: 203-773-3000 Fax: 203-773-1300


SEARCH JOBS

Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.


Key Statistics


Email: info@kolltan.com
Ownership: Private

Web Site: Kolltan Pharmaceuticals Inc.
Employees:
Symbol: 
 









Company News
Kolltan Pharmaceuticals Inc. Presents KTN3379 Clinical And Preclinical Data At International Cancer Meeting 11/20/2014 11:11:07 AM
Kolltan Pharmaceuticals Inc. Begins Phase 1b Cancer Study Evaluating KTN3379 In Combination With Multiple Targeted Therapies At Sarah Cannon Research Institute 11/3/2014 10:41:58 AM
Kolltan Pharmaceuticals Inc. Cancer Study Results For KTN3379, Targeting ErbB3, Support Evaluating Combinations With Targeted Therapies 9/15/2014 12:12:18 PM
Kolltan Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering 9/12/2014 1:59:50 PM
Kolltan Pharmaceuticals Inc. Acquires Xetrios Therapeutics And Exclusive Rights To Salk Institute for Biological Studies Patents Related To The TAM Receptor Tyrosine Kinase Family 9/10/2014 11:19:14 AM
Kolltan Pharmaceuticals Inc. Promotes Jane Henderson To Chief Financial And Business Officer And Expands Senior Team With Appointment Of Keith J. C. Darragh As Vice President Of Finance And Administration 6/27/2014 9:52:33 AM
Kolltan Pharmaceuticals Inc. Expands Company's Board Of Directors 4/16/2014 6:37:36 AM
Kolltan Pharmaceuticals Inc. Hauls In $60 Million Series D Financing 3/26/2014 6:56:09 AM
Kolltan Pharmaceuticals Inc. Initiates Phase 1 Study Of KTN3379, A Dual-Mechanism Anti-Erbb3 Monoclonal Antibody 1/21/2014 9:22:17 AM
Kolltan Pharmaceuticals Inc. Licenses Novel Anti-KIT Antibodies And Related Intellectual Property From The University of Toronto 12/6/2013 9:45:53 AM
12
//-->